-+ 0.00%
-+ 0.00%
-+ 0.00%

Munters Group (OM:MTRS) Stock Price Faces Q3 Results Cash Flow Strain

Simply Wall St·10/23/2026 23:26:31
Listen to the news

Munters Group came into today under pressure, with the share price down about 27% over the past three months and closing at SEK131.45 just before the Q3 2026 report hit. The stock carries a rich P/E multiple of about 47x, so expectations were loaded. Then the headline dropped. Quarterly revenue reached SEK4,473m and basic earnings per share landed at SEK1.16. The immediate question for you as an investor is simple: Does that profit print justify a premium valuation after such a sharp pullback, or has sentiment moved faster than the underlying business?

Love Munters Group’s scale and premium P/E but uneasy about paying up when sentiment has already been hit this hard? Compare it with other high quality companies that pair stronger fundamentals with sturdier balance sheets using our list of solid balance sheet and fundamentals stocks (204 results).

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs Q3 2025): SEK4,473m vs. SEK3,798m (up about 18%)
  • Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): SEK212m vs. SEK192m (up about 10%)
  • Basic EPS (Q3 2026 vs Q3 2025): SEK1.16 vs. SEK1.05 (up about 10%)
  • Trailing 12-month Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): SEK527m vs. SEK784m (down about 33%)

Tired of staring at dense earnings tables and raw figures? Get a clear visual overview of Munters Group, including how its valuation compares with its recent results, in the full company report for Munters Group.

OM:MTRS Trailing 12-Month Earnings & Revenue History as at Oct 2026
OM:MTRS Trailing 12-Month Earnings & Revenue History as at Oct 2026

Munters Group: Backlog Story Meets Execution Reality

Bulls argue that Munters Group will turn its deep data center and AirTech pipeline into richer, more resilient growth rather than just more volume.

"Bullish analysts expect Munters Group to convert its large data center and AirTech order backlog into higher quality growth as it focuses the portfolio on these businesses and scales new capacity."

Q3 order intake up 70%, a 1.6 book to bill and backlog up 178% to SEK28b show the backlog is very real. DCT’s 2.7 book to bill, record net sales and strong service revenue growth mark clear commercial milestones. Pressure on DCT margins and negative operating cash flow mean the quality of that growth is not yet matching the quantity.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Munters Group Bear Case: Profitability Inflection Still Stalled

Bearish analysts frame Munters Group as backlog rich but profit poor, with execution missteps slowing the earnings inflection that is supposed to justify the DCT push.

"Bearish analysts expect Munters Group to struggle to convert its large Data Center Technologies backlog into consistently profitable revenue given recent supply chain issues, tariff effects and slower near term DCT profitability."

Q3 results lean toward that concern. DCT posted record net sales and a 2.7 book to bill, yet segment margins moved the wrong way as tariffs, ramp up inefficiencies in Virginia and component constraints hit profitability and cash. Negative operating cash flow and leverage at 3.4x indicate that the volume surge has not yet translated into healthier earnings quality.

Hunt For Mispriced Earnings Power

Munters Group’s quarter shows how headline growth and earnings quality can pull in different directions. The real opportunity could sit in stocks that seem undervalued before investors recognize their earnings power.

  • Company 1 - 40% below our estimate - captures rising trade in used devices as subsidies and recycling programs steer demand toward structured recommerce platforms.
  • Company 2 - 30% below our estimate - sells high touch consulting work built on local language, regulation know how and sector specific systems expertise.
  • Company 3 - 43% below our estimate - scales new treatments in weight management, menopause and oncology as improved cash conversion supports more focused launches.

Those are three of them. See the full list of 195 companies trading below our fair value estimates →